Lannett receives FDA approval for generic obesity drug

The drug, phentermine hydrochloride, is approved for the short-term management of obesity. Lannett expects to commence marketing the product in June 2005.

Arthur Bedrosian, president of Lannett, was encouraged by the regulatory progress and explained that this would not be the only product the company expects to be releasing. “We currently have nine applications pending at the FDA and a number of other products in various stages of development that will further expand our product offering.”

According to NDC Health, the total US market for phentermine hydrochloride 37.5mg tablets is approximately $84 million. However, there are currently five other generic suppliers marketing this product.